See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

Actos Archives

Diabetes and Actos

Page 2
Black Box Warning For Actos and Avandia

The FDA has spoken: the heart risk warnings on labels of Avandia (rosiglitazone) and Actos (pioglitazone) will now be surrounded by an emphatic black outline known as a black box. Black boxes will also be added to the warnings on Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepiride).

Comments 3 comments - Oct 31, 2007 - * * *

Actos and Avandia Cost Plenty

According to Greek researchers, Actos and Avandia were behind a tripling of the cost of medicines used to treat Athenians with type 2 diabetes over the past eight years.

Comments 0 comments - Oct 10, 2007 - * * *

Actos and Avandia: New Heart Risk Studies

The September 2007 Journal of the American Medical Association (JAMA) has published two new studies, one a meta-analysis of Avandia (rosiglitazone) and the other a meta-analysis of Actos (pioglitazone).

Comments 0 comments - Oct 5, 2007 - * * *

The Latest About Avandia and Actos

On July 30, 2007, a Food and Drug Administration (FDA) panel voted 22 to 1 to keep Avandia on the market, right after agreeing by a vote of 20 to 3 that Avandia does increase heart risks. Now the FDA will decide what kind of warning should appear on the Actos and Avandia labels. It has already called for a black box warning, the sternest possible, on Avandia.

Comments 0 comments - Aug 1, 2007 - * * * *

Amid Accusatory Debate, FDA Puts Black Box Warning on Avandia and Actos

In a congressional hearing on June 13, 2007, the Food and Drug Administration (FDA) revealed that it has called for a black box warning, the sternest possible, on both Actos and Avandia.

Comments 0 comments - Jul 12, 2007 - * * * *

Updated: Analysis Associates Avandia With Greater Risk of Heart Attack

Analysis of several recent studies indicates that Avandia (rosiglitazone), a type 2 diabetes medication that's been taken by more than six million people worldwide, is associated with a 43 percent increased risk of heart attack and with a borderline-significant increased risk of heart attack-related death.

Comments 0 comments - May 31, 2007 - * * * *

Oral Meds Research

Starlix Found to Reduce Liver Fat

Comments 0 comments - Sep 1, 2006 - Not Yet Rated

Actos Alone or Combined With Oral Meds Improves Your Patient’s BGs and Lipids

New Zealand researchers say that in clinical trials of people with type 2 diabetes, Actos as stand-alone therapy or in combination with metformin, repaglinide, insulin or a sulphonylurea induced “both long- and short-term improvements in [blood glucose] control and serum lipid profiles.”

Comments 0 comments - Apr 1, 2006 - Not Yet Rated

Is Pargluva On the Ropes?

It was the belle of the ball at last summer’s ADA Scientific Sessions in San Diego. Now it appears that muraglitazar (Pargluva) is clinging to life after a scathing report recently published by the Journal of the American Medical Association.

Comments 0 comments - Jan 1, 2006 - Not Yet Rated

ACTOplus Met Approved by the FDA for Type 2 Diabetes

In August 2005, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) had approved ACTOplus Met for the treatment of type 2 diabetes.

Comments 0 comments - Nov 1, 2005 - Not Yet Rated

Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.